IQVIA (NYSE:IQV) Stock Rating Upgraded by Barclays

IQVIA (NYSE:IQV) was upgraded by equities research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a report issued on Friday, MarketBeat.com reports. The brokerage currently has a $210.00 price objective on the medical research company’s stock. Barclays‘s price target would suggest a potential upside of 17.65% from the company’s current price.

A number of other research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Truist Financial cut their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Finally, Mizuho set a $215.00 price target on IQVIA in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Stock Up 0.3%

IQVIA stock opened at $178.50 on Friday. The company has a market capitalization of $30.29 billion, a PE ratio of 22.71, a PEG ratio of 1.71 and a beta of 1.39. IQVIA has a 12-month low of $134.65 and a 12-month high of $247.04. The firm’s fifty day moving average is $208.27 and its 200 day moving average is $207.49. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same period in the previous year, the firm posted $3.12 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts predict that IQVIA will post 10.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Brighton Jones LLC boosted its holdings in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after buying an additional 2,537 shares during the last quarter. Empowered Funds LLC raised its position in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new position in IQVIA in the second quarter valued at about $514,000. Huntington National Bank grew its position in shares of IQVIA by 136.6% during the 2nd quarter. Huntington National Bank now owns 899 shares of the medical research company’s stock valued at $142,000 after acquiring an additional 519 shares during the period. Finally, Ellevest Inc. increased its stake in shares of IQVIA by 6.6% during the 2nd quarter. Ellevest Inc. now owns 1,934 shares of the medical research company’s stock worth $305,000 after purchasing an additional 120 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.